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Disease-modifying treatments for
Alzheimer’s disease
Daniela Galimberti and Elio Scarpini
Abstract: The first drugs developed for Alzheimer’s disease (AD), acetylcholinesterase
inhibitors (AChEI), increase acetylcholine levels, previously demonstrated to be reduced in
AD. To date, four AChEI are approved for the treatment of mild-to-moderate AD. A further
therapeutic option available for moderate-to-severe AD is memantine. These treatments are
symptomatic, whereas drugs under development are intended to modify the pathological steps
leading to AD, thus acting on the evolution of the disease. For this reason they are have been
termed ‘disease-modifying’ drugs. To block the progression of the disease they have to
interfere with the pathogenic steps responsible for the clinical symptoms, including the
deposition of extracellular amyloid beta (Ab) plaques and of intracellular neurofibrillary
tangles, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this
review, new perspectives will be discussed. In particular, several approaches will be described,
including interference with Ab deposition by anti-Ab aggregation agents, vaccination,
g-secretase inhibitors or selective Ab-lowering agents; interference with tau deposition by
methylthioninium chloride; and reduction of inflammation and oxidative damage.
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Alzheimer’s disease: pathogenesis and
symptomatic treatments
Alzheimer’s disease (AD) is the most common
cause of dementia in the elderly, with a prevalence
of 5% after65 yearsof age, increasing to about 30%
in people aged 85 years or older. It is characterized
clinically by progressive cognitive impairment,
including impaired judgement, decision-making
and orientation, often accompanied in later stages
by psychobehavioural disturbances and language
impairment. Mutations in genes encoding for
amyloid precursor protein (APP), presenilin 1
(PSEN1) and presenilin 2 (PSEN2) account for
about 5% of cases and are characterized by an
early onset (before 65 years of age). So far, 32 dif-
ferent mutations causing amino acid changes in
putative sites for the cleavage of the protein have
been described in the APP gene in 85 families,
together with 178 mutations in PSEN1 and 14 in
PSEN2 (see http://www.molgen.ua.ac.be/).
The two major neuropathological hallmarks of
AD are extracellular amyloid beta (Ab) plaques
and intracellular neurofibrillary tangles (NFTs).
The production of Ab, which is a crucial step in
AD pathogenesis, is the result of cleavage of APP,
which is overexpressed in AD [Griffin, 2006]. Ab
forms highly insoluble and proteolysis-resistant
fibrils known as senile plaques (SP). NFTs are
composed of the tau protein. In healthy subjects,
tau is a component of microtubules, which are
the internal support structures for the transport
of nutrients, vesicles, mitochondria and chromo-
somes within the cell. Microtubules also stabilize
growing axons necessary for the development
and growth of neurites [Griffin, 2006]. In AD,
tau protein is abnormally hyperphosphorylated
and forms insoluble fibrils, causing deposits
within the cell.
A number of additional pathogenic mechanisms
have been described, possibly overlapping with
Ab plaques and NFT formation, including
inflammation [Galimberti et al. 2008], oxidative
damage [Reddy et al. 2009], iron deregulation
[Adlard and Bush, 2006] and cholesterol metab-
olism [Stefani and Liguri, 2009].
The first drugs developed for AD, acetylcholines-
terase inhibitors (AChEI), were designed to
increase acetylcholine levels, previously demon-
strated to be reduced in AD [Lawrence and
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Sahakian, 1998]. To date, four AChEI have been
approved for the treatment of mild-to-moderate
AD: tacrine (First Horizon Pharmaceuticals),
donepezil (Pfizer), rivastigmine (Novartis) and
galantamine (Janssen) [Farlow, 2002]. Donepezil
is now also approved for severe AD. Although
tacrine was the first drug approved for AD, in
1993, it is rarely used, due to hepatotoxicity.
A meta-analysis of 13 randomized, double-blind,
placebo-controlled trials with donepezil, rivastig-
mine and galantamine was considered by the
Cochrane Dementia and Cognitive Improvement
Group’s Specialized Register. Conclusions were
that the three AChEI are effective for mild-to-mo-
derate AD, although it is not possible to identify
patients who will respond to treatment. There is
no evidence that treatment with an AChEI is not
cost-effective. Despite the slight variations in the
mode of action of the three AChEI, there is no
evidence of any differences among them with
respect to efficacy. There appear to be fewer
adverse effects associated with donepezil than riv-
astigmine. It may be that galantamine and rivas-
tigmine match donepezil in tolerability if a careful
and gradual titration routine over more than
3 months is used. Titration with donepezil is
more straightforward, and the lower dose may be
worth considering [Birks, 2006].
A further therapeutic option for moderate-to-
severe AD is memantine. This drug is an uncom-
petitive, moderate-affinity N-methyl-D-aspartate
(NMDA) antagonist believed to protect neurons
from excitotoxicity. A recent meta-analysis of the
efficacy of AChEIs and memantine indicates that
these treatments can result in statistically signifi-
cant but clinically marginal improvement [Raina
et al. 2008]. Regarding tolerability, AChEIs are
associated with cholinomimetic effects. Nausea
(28%) and vomiting (15%) were reported
across all AChEI trials as the most common rea-
sons for trial discontinuation. Dizziness, anorexia
and diarrhoea were also commonly experienced;
however, improved tolerability has been achieved
with transdermal administration of rivastigmine.
The most frequently reported adverse events in
memantine trials were dizziness, headache and
confusion [Alva and Cummings, 2008].
On the basis of recent additional findings on
AD pathogenesis, novel treatments under devel-
opment aim to interfere with the pathogenic
steps previously mentioned, in an attempt to
block the course of the disease in its early stages
(even preclinical). For this reason they have been
termed ‘disease-modifying’ drugs. In this review,
new compounds and possible strategies for the
development of novel therapies will be discussed
(Table 1).
Disease-modifying treatments: modulation
of amyloid deposition
The amyloid hypothesis
The APP plays a central role in AD pathogenesis
and research as it is the precursor of Ab, which is
the heart of the amyloid cascade hypothesis of AD.
The human APP gene was first identified in 1987,
independently by several laboratories [Goldgaber
et al. 1987; Kang et al. 1987; Robakis et al. 1987;
Tanzi et al. 1987]. The two APP homologues,
APLP1 and APLP2, were discovered several
years later. APP is a type I membrane protein.
Two predicted cleavages, one in the extracellular
domain (b-secretase cleavage) and another in the
transmembrane region (g-secretase cleavage) are
necessary to release Ab from the precursor pro-
tein. Notably, APP is located on chromosome 21
and this provided an immediate connection to the
invariant development of AD pathology in people
with trisomy 21 (Down’s syndrome). The first
mutations demonstrated to be causative of inher-
ited forms of familial AD were identified in the
APP gene, providing evidence that APP plays a
central role in AD pathogenesis. Notably, only
APP, and not its homologues APLP1 and APLP,
contains sequences encoding the Ab domain.
Full-length APP undergoes sequential proteolytic
processing. It is first cleaved by a-secretase (non-
amyloidogenic pathway) or b-secretase (amyloi-
dogenic pathway) within the luminal domain,
resulting in the shedding of nearly the entire ecto-
domain and the generation of a- or b-C-terminal
fragments (CTFs). The major neuronal
b-secretase, named BACE1 (b-site APP cleaving
enzyme), is a transmembrane aspartyl protease
that cleaves APP within the ectodomain, gen-
erating the N-terminus of Ab [Vassar, 2004].
Several zinc metalloproteinases, such as TACE/
ADAM17, ADAM9 and ADAM10, and the
aspartyl protease BACE2, can cleave APP at the
a-secretase site [Allinson et al. 2003] located
within the Ab domain, thus precluding the gener-
ation of intact Ab.
The second proteolytic event in APP processing
involves intramembranous cleavage of a- and
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Table 1. Disease-modifying drugs tested in clinical trials in patients with Alzheimer’s disease.
Name Mode of action Clinical
trial
phase
Results
Drugs influencing
Ab deposition
Anti-amyloid
aggregation agents
Tramiprosate
(AlzhemedTM)
GAG mimetic III No effects on cognition (definitive)
Colostrinin Inhibits Ab aggregation II Modest improvement in
MMSE (not definitive)
Scyllo-inositol
(AZD103)
Inhibits Ab aggregation II Ongoing
Vaccination AN1792 Ab removal (active
immunisation)
II Unclear cognitive results 
severe adverse events
(definitive)
CAD106 II Ongoing
Bapineuzumab Ab removal (passive
immunisation)
III Ongoing
ACC-001 II Ongoing
LY2062430 III Ongoing
MABT5102A I Completed
PF-04360365 I Completed
R1450 I Completed
GSK933776A I Ongoing
V950 I Ongoing
IVIg I Ongoing
SALAs Tarenflurbil
(FlurizanTM)
Inhibits g-secretase III No effects on cognition (definitive)
g-secretase inhibitors LY450139 Inhibits g-secretase III No effects on cognition (definitive)
BMS-708163 II Ongoing
a-secretase
potentiation
Etazolate Increases a-secretase
activity
II Completed
Drugs influencing
tau deposition
MTC (RemberTM) Interferes with tau
aggregation
II Improvement in cognition
(not definitive)
Anti-inflammatory
drugs
Rofecoxib NSAID; inhibits COX2 III No effects on cognition (definitive)
Naproxen Nonselective NSAID III No effects on cognition (definitive)
Diclofenac NSAID II No effects on cognition (definitive)
Celecoxib NSAID II No effects on cognition (definitive)
Hydroxychloroquine NSAID II No effects on cognition (definitive)
Nimesulide NSAID; inhibits COX2 II No effects on cognition (definitive)
Indometacin NSAID II No effects on cognition-toxicity
(definitive)
Drugs preventing
oxidative damage
Folate/B6/B12 Reduction of homocysteine III No effects on cognition (definitive)
Drugs interfering
with metals
PBT2 Metal-protein attenuation II Improvement in cognition
(not definitive)
Clioquinol Inhibits zinc and copper
from binding to Ab
II Reduction in cognitive
decline in more severely
affected patients only
(definitive)
Statins
Simvastatin Cholesterol reduction III Ongoing
Atorvastatin Cholesterol reduction III No effects on cognition (definitive)
Ab: amyloid beta, COX: cyclooxygenase, GAG: glycosaminoglycan, MMSE: mini mental state evaluation, SALAs: selective Ab42-lowering agents.
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b-CTFs by g-secretase, which liberates a 3 kDa
protein (p3) and Ab peptide into the extracellular
milieu. The minimal components of g-secretase
include presenilin PS1 or PS2, nicastrin, APH-1
and PEN-2 [Edbauer et al. 2003]. Biochemical
evidence is consistent with PS1 (or PS2) as the
catalytic subunit of the g-secretase. APH-1 and
PEN-2 are thought to stabilize the g-secretase
complex, and nicastrin to mediate the recruit-
ment of APP CTFs to the catalytic site of the
g-secretase. Major sites of g-secretase cleavage
correspond to positions 40 and 42 of Ab.
Amyloidogenic processing is the favoured path-
way of APP metabolism in neurons because
of the greater abundance of BACE1, whereas
the nonamyloidogenic pathway predominates in
other cell types.
It seems that none of the above-mentioned secre-
tases has unique substrate specificity towards
APP. Besides APP, a number of other transmem-
brane proteins undergo ectodomain shedding by
enzymes with a-secretase activity. Regarding
BACE1, its low affinity for APP led to the
hypothesis that APP is not its sole physiological
substrate. Similarly, PS1 and PS2 play a crucial
role in intramembranous g-secretase cleavage of
several type I membrane proteins other than
APP, including Notch1 receptors and their
ligands [Koo and Kopan, 2004].
A number of functional domains have been
mapped to the extracellular and intracellular
region of APP, including metal (copper and zinc)
binding, extracellular matrix components (hepa-
rin, collagen and laminin), and neurotrophic and
adhesion domains. Thus far, a trophic role for
APP has been suggested, as it stimulates neurite
outgrowth in a variety of experimental settings.
The N-terminal heparin-binding domain of APP
also stimulates neurite outgrowth and promotes
synaptogenesis. In addition, an ‘RHDS’ motif
near the extralumenal portion of APP likely pro-
motes cell adhesion, possibly acting in an integrin-
like manner [Storey et al. 1996].
APP was initially proposed to act as a cell-surface
receptor. Nevertheless, the evidence supporting
this hypothesis has been unconvincing. Only
recently, aside from interactions with extracellu-
lar matrix proteins, has a candidate ligand been
proposed. It was in fact reported that F-spondin,
a neuronal-secreted signalling glycoprotein that
may function in neuronal development and
repair, binds to the extracellular domains of
APP, APLP1 and APLP2 [Ho and Su¨dhof,
2004]. This binding reduces b-secretase cleavage
of APP, suggesting that F-spondin binding may
regulate APP processing.
Drugs interfering with A deposition
Anti-amyloid aggregation agents. The most
studied anti-amyloid aggregation agent is trami-
prosate (AlzhemedTM, Neurochem Inc.), a glycos-
aminoglycan (GAG) mimetic. GAGs binds to
soluble Ab, promoting fibril formation and depo-
sition of amyloid plaques. GAG mimetics compete
for GAG-binding sites, thus blocking fibril for-
mation and reducing soluble Ab [Gervais et al.
2001]. A phase I study in healthy adults demon-
strated that the drug is well tolerated. A 3-month
phase II study was subsequently conducted in
58 patients with mild-to-moderate AD who were
randomized to tramiprosate 50 mg, 100 mg or
150 mg twice a day, or placebo. Patients who com-
pleted the study were eligible for a 21 month open-
label extension with 150 mg twice a day. Baseline
CSF Ab levels declined by up to 70% after
3 months for patients randomly assigned to the
100 mg or 150 mg twice-daily group. However,
no differences were observed in cognitive func-
tions between the tramiprosate and placebo
groups [Aisen et al. 2006]. A phase III study was
then carried out in the US in 1052 patients with
AD to test the drug’s tolerability, efficacy and
safety, but it failed to show any significant effect.
Multiple factors probably contributed to the fail-
ure of the study. Overall, variability among the
67 clinical sites in the trial overwhelmed the
observed treatment effects. Unexpected problems
arose in the control group, confounding the inter-
pretation of efficacy. In particular, 30% of the
control group did not show a decline in cognition
over the 18-month trial period, whereas a portion
of this group unexpectedly showed a significant
improvement in cognition. A similar trial con-
ducted in Europe has been discontinued. In
addition, recent data suggest that tramiprosate
promotes an abnormal aggregation of the tau pro-
tein in neuronal cells [Santa-Maria et al. 2007],
emphasizing the importance of testing on both
types of pathology (amyloid and tau) the potential
drugs for the treatment of AD.
Another molecule under testing is colostrinin,
a proline-rich polypeptide complex derived
from sheep colostrum (O-CLN; ReGen
Therapeutics). Colostrinin inhibits Ab
Therapeutic Advances in Neurological Disorders 4 (4)
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aggregation and neurotoxicity in cellular assays
and improves cognitive performance in animal
models. A 3-week phase I study in patients with
AD demonstrated it is well tolerated [Leszek et al.
1999]. A subsequent phase II trial demonstrated
modest improvements in Mini Mental State
Evaluation (MMSE) scores for patients with
mild AD over a treatment period of 15 months,
but this beneficial effect was not sustained during
an additional 15 months of continued treatment
[Bilikiewicz and Gaus, 2004].
In 2000, McLaurin and colleagues described a
compound named scyllo-inositol, which is able
to stabilize oligomeric aggregates of Ab and inhi-
bit Ab toxicity. Scyllo-inositol dose-dependently
rescued long-term potentiation in mouse hippo-
campus from the inhibitory effects of soluble
oligomers of cell-derived human Ab [Townsend
et al. 2006]. As ELND005 (formerly AZD-103),
scyllo-inositol is being investigated as an orally
administered treatment for AD. A 18-month,
randomized, double-blind, placebo-controlled,
dose-ranging, safety and efficacy study of oral
ELND005 in male and female participants aged
5085 years with mild-to-moderate AD has been
carried out by Transition Therapeutics/Elan.
A long-term follow-up study in subjects with
AD is ongoing (see http://www.clinicaltrials.gov).
Vaccination. In 1999, Schenk and colleagues
demonstrated that immunization with Ab as an
antigen attenuated AD-like pathology in trans-
genic mice overexpressing the APP gene by
removing amyloid from the central nervous
system [Schenk et al. 1999]. This transgenic
mouse model of AD progressively develops sev-
eral neuropathological features of the disease
in an age-related and brain-region-dependent
manner. Immunization of young animals with
Ab prevents the development of plaque forma-
tion, neuritic dystrophy and astroglyosis, whereas
in older animals, vaccination reduces the extent
and progression of AD-like pathologies. Given
these preclinical results, a multicentre, random-
ized, placebo-controlled, phase II double-blind
clinical trial using active immunization with
Ab42 plus adjuvant was started in 2001 on
300 patients using the pre-aggregated Ab peptide
AN1792. However, following reports of aseptic
meningoencephalitis in 6% of treated patients,
the trial was halted after 23 injections. Of the
300 patients treated, 60% developed an antibody
response. The final results of the trial were pub-
lished in 2005 [Gilman et al. 2005].
Double-blind assessment was maintained for
12 months, demonstrating no significant differ-
ences in cognition between antibody responders
and the placebo group for the Alzheimer’s disease
Assessment Scale  Cognitive Subscale (ADAS-
Cog), Disability Assessment for Dementia (DAS),
Clinical Dementia Rating (CDR), MMSE and
Clinical Global Impression of Change (CGIC).
In a small subset of patients, cerebrospinal fluid
(CSF) tau levels were decreased in antibody
responders but Ab levels were unchanged.
Long-term follow-up of treated patients and
further analysis of autopsy data modified and
moderated the negative impact of the first
results, encouraging additional clinical attempts.
Subsequent observations on AN1792-vaccinated
patients or transgenic models, and on brain tissue
derived from mice and humans using a new tissue
amyloid immunoreactivity (TAPIR) method,
suggested that antibodies against Ab-related epi-
topes are capable of slowing the progression of
neuropathology in AD. In a recent 4-year study,
Hock and Nitsch followed 30 patients who
received a primary and booster immunization in
the first year after vaccination, providing further
support for continuing the investigation of anti-
body treatment in AD [Hock and Nitsch, 2005].
In 2008, a paper was published describing the
relationship between Ab42 immune response,
degree of plaque removal and long-term clinical
outcomes [Holmes et al. 2008]. In June 2003,
80 patients (or their caregivers), who had entered
the phase I AN1792 trial in 2000, gave their
consent for long-term clinical follow-up and
post-mortem neuropathological examination. In
patients who received immunization, mean Ab
load was lower than in the placebo group.
Despite this observation, however, no evidence
of improved survival or an improvement in time
to severe dementia was observed in such patients.
Therefore, plaque removal is not enough to halt
progressive neurodegeneration in AD, prompt-
ing some intriguing challenges to the amyloid
hypothesis.
Although severe adverse events occurred in the
first AN1792 trial and cognitive results were
unclear, immunization was not abandoned. The
treatment was, however, modified from active to
passive in order to avoid excessive activation of
the T-cell response and thus prevent complica-
tions. The humanized monoclonal anti-Ab anti-
body bapineuzumab (Wyeth and Elan) has been
D Galimberti and E Scarpini
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tested in a phase II trial in 200 patients with mild-
to-moderate AD. The 18-month, multidose,
one-to-one randomization trial was conducted
at about 30 sites in the US. It was designed to
assess safety, tolerability and standard efficacy
endpoints (ADAS-Cog, DAS) of multiple
ascending doses of bapineuzumab. The 18-
month trial included an interim analysis, and
data collection on clinical endpoints and bio-
markers [Grundman and Black, 2008]. In May
2007, Elan and Wyeth announced plans to start a
phase III clinical trial of bapineuzumab. The
decision to launch phase III studies before the
conclusion of the ongoing phase II was based
on the totality of the accumulated clinical data
from phase I, phase II and a 4.5-year follow-up
study of those patients involved in the original
AN1792 trial.
Among the analyses, different effects were
observed when stratifying patients according to
their apolipoprotein E (ApoE) status. Looking at
the best result of different groupings, it seemed
that a small subset of patients, the ApoE noncar-
riers who received the second-lowest of the four
doses six times, responded truly well by 78 weeks.
Therefore the phase III study was started in
ApoE4 noncarriers with mild-to-moderate AD
(see http://www.clinicaltrials.gov).
Additional antibodies under testing include
ACC-001 (Wyeth, two phase II studies ongoing
in the US and Japan), LY2062430 (solanezumab,
Eli Lilly, a phase III study ongoing), MABT5102A
(Genentech, phase I completed), PF-04360365
(Pfizer, phase I completed), R1450 (Hoffman-
LaRoche, phase I completed), GSK933776A
(GlaxoSmithKline, phase I ongoing) and V950
(Merck, phase I ongoing).
Lastly, natural anti-amyloid antibodies have
been found in human intravenous immunoglobu-
lins (IVIg) obtained from the pooled plasma
of healthy blood donors. In light of these obser-
vations, a phase I trial has been carried out in the
US. Eight AD patients were treated with
IVIg (Gammagard S/D Immune Globulin
Intravenous Human) donated by Baxter
Healthcare Corporation. Seven patients com-
pleted the study. After 6 months, cognitive func-
tion stopped declining in all seven patients
and improved in six of them (see http://
www.alzforum.org). Additional phase I trials are
ongoing [Dodel et al. 2010].
Passive vaccination requires repeated infusions,
and costs are high. Therefore active vaccination
has again been considered, by developing specific
antigens designed to generate high Ab antibody
titres without inducing Ab-reactive T cells. The
first compound tested in patients with AD is
CAD106 (Novartis). Two small studies have
been carried out to evaluate safety, tolerability
and antibody response to three subcutaneous
injections of CAD106 over 12 months. CAD106
was well tolerated and there was a specific Ab-IgG
response in 16/24 patients in cohort I and 18/22
patients in cohort II. A phase II trial is ongoing.
Selective A42-lowering agents. Tarenflurbil is
the first in a new class of drugs, selective Ab42-
lowering agents (SALAs), which modulate
g-secretase activity without interfering with
Notch or other g-secretase substrates [Weggen
et al. 2001]. It binds to a g-secretase site other
than the active/catalytic centre of relevance to
production of Ab42, thereby altering the confor-
mation of g-secretase and shifting production
away from Ab42 without interfering with other
physiologically essential g-secretase substrates.
Tarenflurbil (MPC-7869; Myriad Pharma-
ceuticals; FlurizanTM) is the pure R-enantiomer
of flurbiprofen. It shifts cleavage of APP away
from Ab42, leading to the production of shorter,
nontoxic fragments [Beher et al.2004]. By contrast
with S-flurbiprofen or other nonsteroidal anti-
inflammatory drugs (NSAIDs), it does not inhibit
cyclooxygenase (COX) 1 or COX 2 and is not asso-
ciated with gastrointestinal toxicity [Townsend
and Pratico`, 2005]. In mice, treatment with taren-
flurbil reduces amyloid plaque burden and pre-
vents learning and behavioural deterioration
[Kukar et al. 2007].
A 3-week, placebo-controlled, phase I pharmaco-
kinetic study of tarenflurbil (twice-daily doses of
400, 800 or 1600 mg) in 48 healthy older volun-
teers showed that the drug is well tolerated, with
no evidence of renal or gastrointestinal toxicity.
CSF was collected at baseline and after 3 weeks.
The compound penetrated the bloodbrain bar-
rier in a dose-dependent manner. No significant
changes in Ab42 CSF levels were shown after
treatment. However, higher drug concentrations
in plasma were related to statistically significantly
lower Ab levels [Galasko et al. 2007].
Myriad conducted a 12-month placebo-
controlled phase II trial of tarenflurbil in
Therapeutic Advances in Neurological Disorders 4 (4)
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210 patients with mild-to-moderate AD (MMSE
score: 1526). Patients were randomly assigned
to receive tarenflurbil twice daily (400 mg or
800 mg or placebo) for 12 months. Primary out-
come measures were the rate of change (slope
of decline) of: activities of daily living, quantified
by the Alzheimer’s Disease Cooperative Study 
ActivitiesofDailyLiving inventory (ADCS-ADL),
globalfunction,measuredbytheClinicalDementia
Rating scale Sum of Boxes (CDR-SB) and cog-
nitive function, measured by ADAS-Cog. In a
12-month extended treatment phase, patients
who had received tarenflurbil continued to receive
the same dose, and patients who had received
placebo were randomly assigned to tarenflurbil
at 800 mg or 400 mg twice daily.
A preliminary analysis revealed that patients with
mild AD (MMSE: 2026) and moderate AD
(MMSE: 1519) responded differently to taren-
flurbil according to ADAS-cog and ADCS-ADL;
these groups were therefore analysed separately.
Patients with mild AD in the 800 mg tarenflurbil
group had lower rates of decline than did those in
the placebo group in the activities of daily living,
whereas slowing of cognitive decline did not differ
significantly. In patients with moderate AD,
800 mg tarenflurbil twice daily had no significant
effects on ADCS-ADL and ADAS-Cog and had
a negative effect on CDR-SB. The most common
adverse events included diarrhoea, nausea and
dizziness. Patients with mild AD who were in the
800 mg tarenflurbil group for 24 months had
lower rates of decline for all three primary out-
comes than did patients who were in the placebo
group for months 012 and a tarenflurbil group
for months 1224 [Wilcock et al. 2008].
Given these results, two phase III studies were car-
ried out in the US and Europe. The ActEarliAD
trial was started in 2007 throughout Europe. It is
an 18-month, multinational, randomized, double-
blind, placebo-controlled study in more than
800 patients with AD. Patients enrolled in the
trial were treated with tarenflurbil 800 mg twice
daily or placebo and attended periodic physician
visits for analysis of their performance on memory,
cognition and behavioural tests. The two primary
clinical endpoints were the change in cognitive
decline and function, as measured by ADAS-
Cog, and changes in activity of daily living, as
measured by the ADCS-ADL. A secondary end-
point of the trial was the change in overall
function, measured by CDR-SB. Additional
exploratory outcome measures were designed to
assess the psychological, physical and financial
impact of the disease on caregivers and medical
resources. The trial was designed to meet the
requirements of the European Agency for the
Evaluation of Medicinal Products (EMEA) for
the marketing of tarenflurbil in Europe. The
global endpoints in the European trial were iden-
tical to those in the US trial. As was the case
with the phase II trial, all patients in the phase
III studies were allowed to take current stan-
dard-of -are medicines in addition to tarenflurbil
or placebo, provided their dose had been stable
for 6 months.
Disappointingly, in July 2008, the sponsor
announced that tarenflurbil had failed its defini-
tive phase III trial and would not be developed
further (see http://www.alzforum.org). In fact, on
both primary efficacy endpoints (the ADAS-cog
and ADCS-ADL scales), the treatment and pla-
cebo curves overlapped almost completely, and
there was no effect whatsoever in the group as a
whole. In addition, although the overall side-
effect profile was similar between placebo and
treatment groups, anaemia, infections and gas-
trointestinal ulcers appeared more often in the
tarenflurbil group than in the placebo group.
-secretase inhibition. Several compounds that
inhibit g-secretase activity in the brain have been
identified. Nevertheless, g-secretase has many
biologically essential substrates [Pollack and
Lewis, 2005]. One of the most physiologically
important g-secretase substrate is the Notch sig-
nalling protein, which is involved in the differen-
tiation and proliferation of embryonic cells,
T cells, gastrointestinal goblet cells and splenic
B cells. Experience with transgenic mice has
shown that the administration of a g-secretase
inhibitor in doses sufficient to lower Ab concen-
trations interferes with lymphocyte differentia-
tion [Wong et al. 2004]. Safety is therefore a
very important consideration for this class of
compound.
A nonselective g-secretase inhibitor, LY450139
(Eli Lilly), has been evaluated in a phase I placebo-
controlled study in 37 healthy adults (at doses
ranging from 5 to 50 mg). Ab CSF levels were
reduced in both the active treatment and placebo
groups, but differences were not statistically sig-
nificant. Transient gastrointestinal adverse effects
(bleeding, abdominal pain) were reported by two
subjects treated with 50 mg [Siemers et al. 2005].
A subsequent phase II randomized, controlled
D Galimberti and E Scarpini
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trial was carried out in 70 patients with AD.
Patients were given 30 mg for 1 week followed by
40 mg for 5 weeks. Treatment was well tolerated.
No significant changes in plasma and CSF Ab40
and Ab42 were observed [Siemers et al. 2006].
Subsequently, a multicentre, randomized, double-
blind, dose-escalation, placebo-controlled trial
was carried out. Fifty-one patients with mild-to-
moderate AD were randomized to receive placebo
or LY450139 (100 mg or 140 mg). The LY450139
groups received 60 mg/day for 2 weeks, then
100 mg/day for 6 weeks, then either 100 or
140 mg/day for an additional 6 weeks. Primary
outcomes included safety, tolerability and CSF/
plasma Ab levels; secondary outcome was neuro-
psychological testing. LY450139 was well toler-
ated at doses up to 140 mg/day for 14 weeks.
Plasma Ab, but not CSF, levels were reduced
in treated patients, consistent with inhibition of
g-secretase. No differences were seen in cognitive
or functional measures [Fleisher et al. 2008].
A potent g-secretase inhibitor, BMS-708163
(Bristol-Myers Squibb), was tested in a phase I
clinical trial. After 18 days, BMS-708163
decreased CSF Ab40 and Ab42 by 30% following
a daily dose of 100 mg and by 60% at daily dose
of 150 mg. A phase II study is ongoing (see http://
www.alzforum.org).
-secretase potentiation. Etazolate (EHT 0202,
ExonHit Therapeutics) stimulates the neuro-
trophic a-secretase (nonamyloidogenic) pathway
and inhibits Ab-induced neuronal death, provid-
ing symptomatic relief and modifying disease
progression. In vitro, it is neuroprotective against
Ab42, and neuroprotection is associated with
sAPPa induction [Marcade et al. 2008]. After a
phase I study in healthy volunteers, a phase II
clinical trial has been recently completed that
assessed safety, tolerability and preliminary effi-
cacy on cognition and behaviour in AD patients,
as well as quantification of sAPPa in blood (see
http://www.alzforum.org).
-site APP cleaving enzyme inhibition. Research
into compounds able to inhibit b-site APP cleav-
ing enzyme (BACE) is still in the preclinical
phase. The pharmacophore model of arylpipera-
zine amide derivatives was built using the
Discovery Studio 2.0 software package and the
best pharmacophore model was validated by
enrichment and the receiver operating charac-
teristic (ROC) method. According to the best
model, 11N-phenyl-1-arylamide, N-phenyl-
benzenesulfonamide derivatives, compounds
2628, and 33a33g, were designed to be syn-
thesized and their BACE 1 inhibitory activities
were determined experimentally. The theoretical
results were in good agreement with the experi-
mental values. Compound 33d, which displayed
the highest BACE 1 activity among the two
series, was chosen to study the protein binding
pattern and the result showed that it was in close
contact with two essential catalytic aspartates
(Asp32 and Asp228) of the BACE 1 [Huang
et al. 2008]. Other compounds with a potential
BACE1 inhibitory effect include neocorylin [Choi
et al. 2008], epigallocatechin-3-gallate and curcu-
min [Shimmyo et al. 2008] and N (4)-substituted
piperazine naphthamide derivatives [Laras et al.
2009].
Disease-modifying treatments:
modulation of tau deposition
Tau and Alzheimer’s disease
Tau is relatively abundant in neurons but is
present in all nucleated cells and functions physi-
ologically to bind microtubules and stabilize
microtubule assembly for polymerization. The
tau-encoding gene (MAPT; Microtubule
Associating Protein Tau) consists of 16 exons. In
the adult brain, alternative splicing of tau nuclear
RNA results in six tau isoforms having either three
or four peptide repeats of 31 or 32 residues in the
C-terminal region encoded on exon 10, compris-
ing the microtubule binding domain, or differing
in the expression of zero, one or two inserts
encoded on exon 2 and 3. During neurodegenera-
tion, tau is abnormally phosphorylated. The pro-
file of alternative splicing differs among
pathological phenotypes, such that tau accumula-
tion in AD is a mixture of 3R and 4R tau, Pick’s
disease tends to be 3R tau, corticobasal degener-
ation and progressive supranuclear palsy tend to
be 4R tau, and so-called argyrophilic grain disease
accumulates small inclusions of 3R tau [Castellani
et al. 2008].
Drugs interfering with tau deposition
A phase II trial of a tau-blocking compound
named methylthioninium chloride (MTC) is
ongoing (TauRx Therapeutics, RemberTM).
This is a reducing agent better known as methy-
lene blue, a deep blue dye used in analytical
chemistry, as a tissue stain in biology, and in var-
ious industrial products. MTC interferes with
tau aggregation by acting on self-aggregating
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truncated tau fragments [Wischik et al. 1996].
The company conducted a phase II trial random-
izing 321 patients with mild or moderate AD to
treatment with either placebo or one of three oral
doses of MTC: 30 mg, 60 mg or 100 mg three
times daily. Patients were not taking AChEI or
memantine. Primary outcomes were to compare
the effect of MTC with that of placebo on cog-
nitive abilities measured by the ADAS-Cog at
24 weeks. Preliminary results were presented at
the 2008 International Conference on Alzheimer’s
Disease. The 100 mg dose was found to have a
formulation defect limiting release of the thera-
peutic form of MTC, therefore this arm was
discontinued. In CDR-moderate subjects at the
60 mg dose, a significant improvement was shown
relative to placebo of 5.4 ADAS-Cog units.
There was no placebo decline in CDR-mild AD
over the first 24 weeks, preventing initial efficacy
analysis. A problem with the use of this drug is
that urine becomes blue, resulting in a lack
of blinding. These preliminary results need to
be considered cautiously until definitive data
are published.
An interesting approach to block tau deposition
is to inhibit kinases responsible for tau hyperphos-
porylation. Despite the large number of tau phos-
phorylation sites and the ability of multiple kinases
to phosporylate individual sites, glycogen synthase
kinase 3 (GSK3b) has emerged as potential ther-
apeutic target [Balaraman et al. 2006]. The most
studied compound able to inhibit GSK3 is lith-
ium, but several other compounds are under
development, including pyrazolopyrazines, pyra-
zolopyridines, the aminothiazole AR-A014418,
and sodium valproate [Martinez and Perez,
2008; Schneider and Mandelkow, 2008].
Similarly to AD, vaccination approaches have
been considered, but the development of a suc-
cessful therapy is complicated by the fact that tau
protein is intracellular.
Disease-modifying treatments: modulation
of inflammation and oxidative damage
Anti-inflammatory drugs
Epidemiological evidence suggests that long-
term use of NSAIDs protects against the devel-
opment of AD [McGeer et al. 1996]. Despite this
premise, prospective studies of rofecoxib [Reines
et al. 2004], naproxen [Aisen et al. 2003], diclo-
fenac [Scharf et al. 1999], celecoxib [Soininen
et al. 2007], dapsone [Eriksen et al. 2003],
hydroxychloroquine [Aisen et al. 2001] and
nimesulide [Aisen et al. 2002] failed to slow pro-
gression of cognitive decline in patients with
mild-to-moderate AD. By contrast, indometacin
may delay cognitive decline in this subset of
patients, but gastrointestinal toxicity is treat-
ment-limiting [Rogers et al. 1993]. Because of
general concerns about lack of efficacy, gastroin-
testinal toxicity, myocardial infarction and stroke,
NSAIDs are not considered to be viable treat-
ment options for patients with AD.
Molecules addressing oxidative damage
A trial to determine whether the reduction of
homocysteine levels with high-dose folate, vitamin
B6 and vitamin B12 supplementation can slow
the rate of cognitive decline in subjects with AD
has been tried in a multicentre, randomized, con-
trolled clinical trial named VITAL (VITamins to
slow ALzheimer’s disease). The study included
409 individuals with mild-to-moderate AD
(MMSE between 14 and 26) and normal folic
acid, vitamin B12 and homocysteine (Hcy) levels.
Participants were randomly assigned to two
groups of unequal size (60% treated with high-
dose supplements: 5 mg/day folate, 25 mg/day
vitamin B6 and 1 mg/day vitamin B12; and 40%
treated with identical placebo); duration of treat-
ment was 18 months. The main outcome measure
was the change in the ADAS-Cog score. A total of
340 participants completed the trial. Although the
vitamin supplement regimen was effective in
reducing Hcy levels, it had no beneficial effect
on the primary cognitive measure, the rate of
change in ADAS-Cog score over 18 months, or
on any secondary measures [Aisen et al. 2008].
Additional potential antioxidants include
mitoquinone (Antipodean Pharmaceuticals),
vitamin E, Ginkgo biloba and natural polyphenols
such as green tea, wine, blueberries and curcu-
min. Clinical trial with vitamin E and omega-3
fatty acids did not show beneficial effects in AD
patients [Barten and Albright, 2008].
Disease-modifying treatments:
additional approaches
Drugs interfering with metals
In 1994 it was observed that Ab becomes amyloi-
dogenic upon reaction with stoichiometric
amounts of Zn2þ and Cu2þ [Bush et al. 1994].
Ab is rapidly precipitated by Zn2þ. Cu2þ and
Fe3þ also induce marked Ab aggregation, but
only under mildly acidic conditions [Bush,
D Galimberti and E Scarpini
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2008], such as those believed to occur in the brains
of people with AD. The precipitation of Ab by
these ions is reversible with chelation, by contrast
with fibrillization, which is irreversible. Cu, Fe
and Zn play a greater role than merely assembling
Ab. When binding Cu2þ or Fe3þ, Ab reduces the
metal ions and produces H2O2 by double electron
transfer to O2. In addition, Ab promotes the
Cu-mediated generation of the toxic lipid oxida-
tion product 4-hydroxynonenal [Bush, 2008].
PBT2, an analogue of clioquinol, was designed to
modify the course of AD by preventing metal-
dependent aggregation, deposition and toxicity
of Ab. PBT2 acts at three levels of the ‘amyloid
cascade’: it inhibits the redox-dependent forma-
tion of toxic soluble oligomers, prevents deposi-
tion of Ab as amyloid plaques, and promotes
clearance by mobilizing and neutralizing Ab
from existing deposits [Cherny et al. 2001].
PBT2 has been recently tested in a phase II
trial. Seventy-eight patients with mild AD were
randomly assigned to PBT2 50 mg, PBT2
250 mg or placebo (in addition to AChEI) for
12 weeks. No serious adverse events were
reported by patients on PBT2. Patients treated
with PBT2 250 mg had a dose-dependent and
significant reduction in CSF Ab42 concentration,
compared with those treated with placebo
[Lannfelt et al. 2008]. Cognitive efficacy was,
however, restricted to two measures only, there-
fore future larger and longer trials are needed to
test the efficacy of this drug on cognition.
The parent compound, clioquinol (PBT1, Prana
Biotechnology), was tested in a clinical trial for AD
that showed a reduction in the rate of cognitive
decline in the more severely affected subgroup
of patients only [Ritchie et al. 2003]. According
to a Cochrane Collaboration study, it was not
clear from this trial whether clioquinol showed
any positive clinical result. The two statistically
significant positive results were seen for the more
severely affected subgroup of patients; however,
this effect was not maintained at the 36-week end-
point, and this group was small (eight treated
subjects). The sample size was small. Details of
randomization procedure or blinding were not
reported [Jenagaratnam and McShane, 2006].
Modulation of cholesterol and vascular-related
risk factors
It has repeatedly been shown that ApoE carriers
have a higher risk of developing AD. Because
ApoE is the major cholesterol transporter in the
central nervous system, a link between cholesterol
and AD is suggested. The brain is the most
cholesterol-rich organ of the body, and most of
the cholesterol is synthesized in astrocytes.
A link between hypercholesterolemia, cardiovas-
cular diseases and AD has also been suggested.
Additional vascular-related risk factors for AD
include hypertension, atrial fibrillation, hyper-
homocysteinemia, atherosclerosis and stroke
[Hooijmans et al. 2008].
Hypertension is the strongest risk factor for AD
and vascular dementia when these conditions are
considered together [Skoog et al. 1996]. It is clo-
sely associated with atherosclerosis and vascular
function, and in the brain results in hypoperfu-
sion and ischemic conditions of the nucleus basa-
lis of Meynert. The use of targeted molecular
mechanisms and dietary methods and therapies
is grounded in reducing free radicals and associ-
ated oxidative stress-related damage initiating
hypertension [Vasdev et al. 2007].
Epidemiological studies have indicated that
patients treated for cardiovascular disease with
cholesterol-lowering therapy (statins) showed a
decreased prevalence of AD [Jick et al. 2000].
Simvastatin is a prodrug, hydrolyzed in vivo to gen-
erate mevinolinic acid, an active metabolite that is
structurally similar to HMG-CoA. This metabo-
lite competes with HMG-CoA for binding HMG-
CoA reductase, a hepatic microsomal enzyme.
Simvastatin metabolites are high-affinity HMG-
CoA reductase inhibitors, reducing the quantity
of mevalonic acid, a precursor of cholesterol.
CLASP is an ongoing randomized, double-blind,
placebo-controlled, parallel-assignment phase III
trial to investigate the safety and effectiveness
of simvastatin to slow the progression of AD.
The clinical trial involves 400 participants with
mild-to-moderate AD, and the objective is to
evaluate the safety and efficacy of simvastatin
to slow the progression of AD, as measured
by ADAS-Cog. Measures of clinical global
change (ADCS-CGIC; Alzheimer’s Disease
Cooperative Study  Clinical Global Impression
of Change), mental status, functional ability,
behavioural disturbances, quality of life and eco-
nomic indicators will also be made. The study
medication will be as follows: 20 mg simvastatin
or matching placebo to be given for 6 weeks, fol-
lowed by 40 mg simvastatin or matching placebo
for the remainder of the 18-month study period
(see http://www.clinicaltrials.gov).
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The Lipitor’s Effect in Alzheimer’s Dementia
(LEADe) study tests the hypothesis that a statin
(atorvastatin 80 mg daily) will provide a benefit
on the course of mild-to-moderate AD in patients
receiving background therapy of donepezil 10 mg
daily. An international, multicentre, double-
blind, randomized, parallel-group study with a
double-blind randomized withdrawal phase in
patients with mild-to-moderate AD (MMSE¼
1325) was carried out. Inclusion criteria
included age 5090 years, receiving donepezil
10 mg for at least 3 months before randomiza-
tion, and low-density lipoprotein choles-
terol levels (LDL-C) 2.5 to 3.5 mmol/l
(95195 mg/dl). Co-primary endpoints were
changes in ADAS-Cog and ADCS-CGIC
scores. A confirmatory endpoint was rate of
change in whole brain and hippocampal volumes
in patients who were enrolled in the magnetic
resonance imaging substudy [Jones et al. 2008].
Despite a promising premise, there were no sig-
nificant differences in the co-primary endpoints
of ADAS-Cog or ADCS-CGIC, or the secondary
endpoints, although atorvastatin was generally
well tolerated [Feldman et al. 2010].
Final remarks
From data presented in this review, three main
considerations have emerged that should be
taken into account when planning future clinical
trials.
First, the mechanisms underlying the pathogen-
esis of AD need to be thoroughly investigated
before starting the development of novel com-
pounds claimed to be disease-modifying.
Despite promising premises related to the so-
called amyloid hypothesis and other pathogenic
mechanisms, large phase III trials with potentially
disease-modifying properties have failed to dem-
onstrate any effect on cognition. A good lesson
comes from the neuropathological analysis of
brains from patients who received immunization,
which demonstrated that although mean Ab load
was lower than in the placebo group, there was
no evidence of improved survival or improvement
in time to severe dementia. Plaque removal there-
fore seems not to be sufficient to halt progressive
neurodegeneration in AD, prompting some
intriguing challenges to the amyloid hypothesis.
In light of these considerations, it is of crucial
importance to better understand the relationship
between tau, Ab and other factors for developing
novel potentially disease-modifying drugs.
The second point to be addressed is that treat-
ments for AD appear effective only in certain
phases of the disease. A few disease-modifying
compounds showed some benefits in mild but
not moderate AD. The same was observed for
anti-inflammatory drugs, for which recent studies
have demonstrated a high degree of inflammation
in very mild but not in severe AD. Therapeutic
trials should therefore be carried out as early as
possible during the course of the disease, which
requires the identification of more accurate tools
for early diagnosis. In this regard, new research
diagnostic criteria for early and specific diagnosis
were proposed in 2007 [Dubois et al. 2007], intro-
ducing the use of CSF analysis, structural and
functional imaging and genetics, together with
classical neuropsychological testing. Large-scale
international controlled multicentre trials are
engaged in phase III development of the feasible
core imaging and CSF biomarker candidates
in AD (US, European, Australian and Japanese
AD Neuroimaging Initiative, and the German
Dementia Network). If validation of these new cri-
teria is to be achieved, they should be considered
in the setting of future clinical trials to identify
more homogeneous study groups.
Last, indicators useful as surrogate outcome
measures (surrogate biomarkers) should be iden-
tified in order to have substitutes for clinical end-
points (i.e. neuropsychological testing), tools able
to predict clinical benefit or the opposite, and
to demonstrate whether the drug has disease-
modifying properties. So far, no biomarker pro-
posed for early diagnosis has been validated as a
surrogate marker for monitoring treatments.
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